Loading...
Loading...
CABA| Name | Value |
|---|---|
| Revenues | 1.6M |
| Cost of Revenue | 0.8M |
| Gross Profit | 0.8M |
| Operating Expense | 33.8M |
| Operating I/L | -33.8M |
| Other Income/Expense | 1.2M |
| Interest Income | 1.9M |
| Pretax | -32.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -32.6M |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell-mediated autoimmune diseases. Their proprietary technology uses chimeric autoantibody receptor (CAAR) T cells to target and eliminate disease-causing B cells. Their lead product candidate, DSG3-CAART, is in Phase I clinical trial for mucosal pemphigus vulgaris and Hemophilia A with Factor VIII alloantibodies. The company's product candidate pipeline includes MuSK-CAART and FVIII-CAART for myasthenia gravis and Hemophilia A, respectively, as well as DSG3/1-CAART for mucocutaneous pemphigus vulgaris.
